EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Dec 9, 2011
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
Successful human placentation depends on adequate transformation of the uteroplacental vasculature by extravillous trophoblast (EVT) following proliferation, migration, and invasion of these cells into the maternal decidua. This process of vascular remodelling rises to a peak by the end of the first trimester and declines rapidly thereafter. Poor invasion can lead to the development of pathological condition such as Pre-eclampsia (PE) and intrauterine growth restriction (IUGR). PE affects 5-6 % of pregnancies in France and causes the death of ten or so women per year. Our research project i...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women older than 17 years old
- • All pregnant patients enrolled before 14 SG and with singleton, irrespectively of their parity
- • Pregnant woman living in the Grenoble area
- • Women accepting, the participation to the study.
- Exclusion Criteria:
- • Inability to understand the project
- • Persons deprived of their liberty by judicial or administrative decisions
- • Person under legal protection
About Institut National De La Santé Et De La Recherche Médicale, France
The Institut National de la Santé et de la Recherche Médicale (INSERM) is France's key public research organization dedicated to advancing knowledge in health and biomedical sciences. Established to foster innovation and improve public health outcomes, INSERM conducts a wide range of clinical trials and research initiatives aimed at translating scientific discoveries into effective medical treatments and interventions. With a focus on collaboration among researchers, healthcare professionals, and industry partners, INSERM plays a pivotal role in shaping health policies and enhancing the quality of care in France and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, Isere, France
Patients applied
Trial Officials
Pascale Hoffmann, MD/PHD
Principal Investigator
University Hospital, Grenoble
Nadia ALFAIDI, PHD
Study Director
inserm U878
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials